Stockreport

Conatus Announces Completion of Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated NASH Cirrhosis

CONATUS PHARMACEUTICALS INC  (CNAT) 
Last conatus pharmaceuticals inc earnings: 11/5 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.conatuspharma.com/investor-relations
PDF SAN DIEGO, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the completion of enrollment in ENCORE-LF, a Phase 2b clinical [Read more]